Home
About
Technology
Licensing Opportunities
Investors
Education
Events
Contact

Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results

Lexaria’s DehydraTECH technology proven to assist in delivery of nicotine across the blood-brain-barrier in animal studies.

Subscribe now to receive our

NEWS & UPDATES

Name
First Last
Email*

Lexaria Bioscience Corp. (CSE:LXX; NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Home
About
Technology
Licensing Opportunities
Investors
News
Blog
Education
Events
Contact

250.765.6424
[email protected]

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Copyright © 2021 All rights reserved. Web Design, Kelowna Photographers, SEO by Hiilite

Lexaria Bioscience Advances 2021 Strategic Initiatives

Lexaria Focusing on Four Core Business Segments:
• Heart disease including hypertension
• Reduced-risk non combusted nicotine
• Improved antiviral drug delivery
• CBD from hemp